Expertise in
3
conditions

Bertrand Routy

Montreal, QC, CA 
Expertise in
3
conditions
Montreal, QC, CA 

Overview

Bertrand Routy practices practicing medicine in Montreal, Canada.

Mr. Routy is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Melanoma, Splenectomy, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 149 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Montreal, QC, Canada
Other Locations
Canada
Quebec, QC, Canada
Toronto, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and Melanoma
Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and Melanoma
Enrollment Status: Completed
Publish Date: July 30, 2025
Intervention Type: Biological
Study Phase: Phase 1
Phase II Trial of Fecal Microbial Transplantation in Patients With Advanced Non-Small Cell Lung Cancer and Melanoma Treated With Immune Checkpoint Inhibitors.
Phase II Trial of Fecal Microbial Transplantation in Patients With Advanced Non-Small Cell Lung Cancer and Melanoma Treated With Immune Checkpoint Inhibitors.
Enrollment Status: Unknown
Publish Date: August 07, 2024
Intervention Type: Combination product
Study Drug: FMT+ICI
Study Phase: Phase 2
Lung Cancer Cryo-Activation as a Novel Approach to Improve Cancer Immunogenicity and Augment Immunotherapy Efficacy
Lung Cancer Cryo-Activation as a Novel Approach to Improve Cancer Immunogenicity and Augment Immunotherapy Efficacy
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Procedure, Drug
Study Phase: Not Applicable
View 2 Less Clinical Trials

149 Total Publications

Dietary intervention through bacterial-derived butyrate elicits anti-tumor activity and increases anti-PD-1 response.
Dietary intervention through bacterial-derived butyrate elicits anti-tumor activity and increases anti-PD-1 response.
Journal: Gut microbes
Published: July 15, 2026

Frequently Asked Questions about Bertrand Routy

Is Bertrand Routy a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Bertrand Routy is classified as an Distinguished expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Bertrand Routy participate in research or clinical trials?

Yes. Bertrand Routy has published 149 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Bertrand Routy's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Routy's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile